Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ --

  • Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60
  • Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP EPS Guidance of $2.54-$2.56
  • Delivers Revenue of $4.658 Billion, an Increase of 3.3 Percent (Up 3.6 Percent Excluding Foreign Exchange); Revenue Up 10.9 Percent Excluding Exchange and TriCor/Trilipix Due to Loss of Exclusivity
  • Revenue Growth Reflects 19.1 Percent Global Sales Growth from HUMIRA and Strong Growth from Other Products Including Synthroid, Creon, Zemplar and Duodopa
  • Strong R&D Investment Supports Pipeline Advancements Including the Initiation of a Large Single-Agent Study of ABT-199 in CLL, Start of a Second Phase 3 Study of Elagolix in Endometriosis, and Significant Progress Toward the Completion of our Comprehensive Global Phase 3 HCV Program
  • Continues to Enhance Early-Stage Pipeline with Two New Collaborations in Inflammatory Diseases and Cystic Fibrosis
  • AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2013.

    "Our third-quarter performance demonstrates the strength and durability of our product portfolio and the continued execution of our key strategic priorities as an independent biopharmaceutical company," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.  "Our mid- to late-stage pipeline contains a number of potentially significant opportunities, and we look forward to a series of milestones across our pipeline in the coming months."

    Third-Quarter Results

  • Worldwide sales were $4.658 billion in the third quarter, up 3.3 percent.  On an operational basis, sales increased 3.6 percent, excluding a 0.3 percent unfavorable impact from foreign exchange rate fluctuatio
    '/>"/>

  • SOURCE AbbVie
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. AbbVie Named a Science Top Employer
    2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
    6. AbbVie Declares Quarterly Dividend
    7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
    9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
    10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
    11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
    (Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
    (Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
    Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
    ... SCHAUMBURG, Ill. , Jan. 19 ... pharmaceutical company, today announced that it has launched ... per 10 mL and 90 mg per 10 mL.  Pamidronate disodium ... Aredia®, is a bone resorption inhibitor.  The 2008 ...
    ... , FRANKLIN LAKES, N.J. , Jan. ... MHS ) are scheduled to present at the following investor conferences: , ... the Jeffries 2010 Global Healthcare Services Conference on Monday, January 25, ... hotel in New York ; , David B. Snow Jr. ...
    Cached Medicine Technology:Sagent Pharmaceuticals Launches Pamidronate Disodium Injection 2Medco to Present at Upcoming Investor Conferences 2
    (Date:7/12/2014)... (PRWEB) July 12, 2014 The Passenger ... million in 2013 to $20,341.36 million by 2019, at ... 2013 and 2019. , The public transport infrastructure in ... is also available in almost every corner of the ... the interest of public transport service providers are driving ...
    (Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives (Plasticizers, ... & Geography – Trends & Forecast to 2018," defines ... of market volume and value. The report also estimates ... market of phthalic anhydride is projected to grow from ... by 2018, with a CAGR of 5.24% from 2013 ...
    (Date:7/12/2014)... 12, 2014 In this ... ‘cognitive assessment and training’ is defined as ... train, or enhance cognitive functions. These solutions ... in dementia screening, clinical trials, driver’s safety, ... self assessment, brain training, and employers’ assessment ...
    (Date:7/12/2014)... 12, 2014 The fastest-growing mobile technology ... and measurement of LTE networks continues to grow due ... smart devices have increased mobile data traffic, which is ... (CT&M) market. Communications Test and Measurement equipment comply with ... The Communications Test and Measurement Market is estimated to ...
    (Date:7/12/2014)... make exercise fun, you,ll eat less after your workout, new ... on a 1.4-mile walk and were either told it would ... were given lunch after the walk, and those who were ... chocolate pudding for dessert than those who were told it ... were given mid-afternoon snacks after their walk. Those who were ...
    Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2
    ... by the British Heart Foundation says that British Asians are ... to heart disease than people// of European origin. One in ... 3 percent of the general population in the UK. ... diabetes, abnormal cholesterol levels and high blood pressure amongst South ...
    ... Journal of Respiratory and Critical Care Medicine says that ... the blood could// help detect abnormal lesions like cancer ... of inflammation and measuring the blood levels of this ... developing lesions that could cause irreversible damage. ...
    ... components such as polyphenols. This is essential in preventing periodontal ... found to affect the gums and the bone that surrounds ... factor in preventing it. ,If not prevented ... Statistics show that about 15 % of those aged 21 ...
    ... come to an end after the health authorities promised to pay ... and working hours//. ,As word spread that the doctors ... Long queues were seen in the city's hospitals. ,'It ... son's eye surgery was fixed for Sunday and we were wondering ...
    ... An overseas-trained doctor, Farid Zaer, who has registered himself ... to Queensland, to continue his medical practice.// The doctor ... been accused for wrong diagnosis involving nearly 208 patients. ... work as a GP, without any restriction or supervision. ...
    ... of the oral cavity can be effectively treated by ... at Buffalo's School of Dental Medicine. ,Photodynamic ... currently employed in the treatment of Kaposi's sarcoma, breast ... the esophagus. ,The treatment modality involves administration ...
    Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:Infections Of The Oral Cavity Can Be Treated By Photodynamic Therapy 2
    ...
    ... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
    Stylish yet conservative, these classics are reliable, comfortable and durable....
    Inquire...
    Medicine Products: